Vernalis Inks Specialty Pharma Deal with Tris, Raises $103.8M
LONDON – Vernalis plc has taken the decisive step in casting off its biotech roots, announcing a £65.9 million (US$103.8 million) fundraising that will enable it to enter the U.S. prescription drug market and also catapults the company's market capitalization from £20 million to £100 million.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter